Skip to search formSkip to main contentSkip to account menu

rozrolimupab

Known as: Symphoglobulin-D 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Immunoglobulin GRecombinant Proteins

Narrower (1)

SYM001

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia
Introduction: Over the last decade the field of medicine has dramatically changed with the introduction of biological therapies… 
Review
2013
Review
2013
Rozrolimupab, a mixture of recombinant human monoclonal anti‐D antibodies, for the treatment of primary immune thrombocytopenia – a review
In patients with immune thrombocytopenia (ITP) who are Rhesus (Rh) D positive and who have not undergone splenectomy, the… 
2012
2012
Are 25 antibodies better than 1?
In this issue of Blood , Robak et al present data suggesting that rozrolimupab, a first-in-class mixture of 25 recombinant… 
2011
2011
Final Results From a Phase II Trial with the First in Class Recombinant Polyclonal Antibody Product Rozrolimupab in Primary Immune Thrombocytopenia
Abstract 527 Background: Rozrolimupab is the first in-class fully human, recombinant antibody mixture for the treatment of ITP… 
2011
2011
Expression and Immunomodulatory Function of RANKL in Leukemia
Abstract 245 The TNF family member RANKL and its receptors RANK and osteoprotegerin (OPG) are key regulators of bone remodelling… 
2010
2010
Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura.
  • R. Stasi
  • Current opinion in molecular therapeutics (Print)
  • 2010
  • Corpus ID: 24006055
Currently under codevelopment by Symphogen and Swedish Orphan Biovitrum, rozrolimupab is the first in a new class of recombinant… 
Review
2010
Review
2010
FDA Pipeline Preview, November 2010 (Qnexa, Linjeta, JZP-6, Bydureon, Zalbin, Staccato loxapine, Tapentadol extended-release oral analgesic, AVP-21D9, 1% tenofovir vaginal gel, AFM 13, hGH-CTP…
Recent FDA action (through, October 2010) related to Qnexa, Linjeta, JZP-6, Bydureon, Zalbin, Staccato loxapine, Tapentadol… 
2009
2009
Gateways to clinical trials.
(-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)